Search

Your search keyword '"MAGRI V"' showing total 116 results

Search Constraints

Start Over You searched for: Author "MAGRI V" Remove constraint Author: "MAGRI V" Search Limiters Full Text Remove constraint Search Limiters: Full Text
116 results on '"MAGRI V"'

Search Results

1. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients

Catalog

Books, media, physical & digital resources

3. An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile

4. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

5. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

6. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis

7. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

8. Influence of dietary energy intake on nephrolithiasis - A meta-analysis of observational studies

9. Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series

10. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

11. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

12. Gram-positive microorganisms isolated during Chronic Bacterial Prostatitis investigation

13. OncotypeDX® predictive nomogram for recurrence score output: A machine learning system based on quantitative immunochemistry analysis - ADAPTED01

14. Abstract P4-13-07: SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC)

15. Abstract P5-12-08: Not presented

16. OncotypeDX (R) predictive nomogram for recurrence score output: A machine learning system based on quantitative immunochemistry analysis-ADAPTED01

18. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

19. P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience

21. Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence

22. Αιμοσπερμία: Πολύ κακό για το τίποτα;.

24. Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)

25. Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)

26. 326P - Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

27. Influence of infection on the distribution patterns of NIH-chronic prostatitis symptom index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

28. Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)

29. D27 - Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence

33. Efficacy of Chemotherapy (CHT) Beyond Tyrosine Kinases Inhibitors (TKI) in Advanced Non Small Cell Lung Cancer (NSCLC) Patients (PTS) Unselected for Epidermal Growth Factor Receptor (EGFR) Mutation

37. Entre écrit et oral - L'anaphore rhétorique dans le discours de campagne. L'exemple de N. Sarkozy

38. Critical issues in chronic prostatitis

39. Paraphrases, périphrases, antonomases et désignation de l’altérité

40. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

41. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

42. Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer

43. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer

44. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

45. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer

46. A cosine based validation measure for Document Clustering

47. Chlamydia trachomatis infection is related to premature ejaculation in chronic prostatitis patients: results from a cross-sectional study

48. The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.

49. Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.

50. 3D cell culture models in research: applications to lung cancer pharmacology.